scholarly journals Frequency of Infectious Agents after Bone Marrow Transplantation in Various Regions of Iran (2001 - 2017): A Systematic Review

2021 ◽  
Vol 25 (4) ◽  
Author(s):  
Mandana Afsharian ◽  
Leila Hamzelo ◽  
Alireza Janbakhsh ◽  
Feizollah Mansouri ◽  
Babak Sayad ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Case Studies ◽  
Marrow Transplantation ◽  
Infectious Agents ◽  
Bone Marrow Transplants ◽  
Transplant Recipients ◽  
Gram Positive ◽  
Gram Positive Bacteria

Context: Infections are a major cause of disease and mortality in transplant recipients. Despite the studies conducted in Iran, no comprehensive and general research is available in this area. The present study aimed to determine the frequency of infectious agents in patients after bone marrow transplantation in Iran. Method: In this systematic review, relevant studies were selected based on type and objective, and data were collected from the articles published in Iran regarding the frequency of infectious agents after bone marrow transplantation in different regions of Iran. The studies were collected using systematic search methods. Results: In total, 11 studies were identified regarding infectious agents after bone marrow transplantation. Six studies were conducted in Tehran, three studies were performed in Shiraz, and Mashhad and Semnan provinces were the locations of two separate studies. Most of the case studies identified viral agents (54.5%; n = 6), followed by fungal infectious agents (27.3%; n = 3) and bacterial agents (18.2%; n = 2). Gram-positive bacteria (bacterial agents), cytomegalovirus (viral agents), and Candida and Aspergillus (fungi) had the highest frequency after bone marrow transplantation. Conclusions: According to the results, viral, fungal, and bacterial infectious agents were respectively most frequent in patients receiving bone marrow transplants. Gram-positive bacteria (bacterial agents), cytomegalovirus (viral agents), and Candida and Aspergillus (fungi) had the highest frequency after bone marrow transplantation.

Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies

Blood ◽  
2004 ◽  
Vol 104 (12) ◽  
pp. 3813-3820 ◽  
Author(s):  
Satoshi Takahashi ◽  
Tohru Iseki ◽  
Jun Ooi ◽  
Akira Tomonari ◽  
Kashiya Takasugi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Cord Blood ◽  
Marrow Transplantation ◽  
Cord Blood Transplantation ◽  
Disease Free Survival ◽  
Hematologic Malignancies ◽  
Adult Patients ◽  
Transplant Recipients ◽  
Blood Transplantation

Unrelated cord blood transplantation (CBT) has now become more common, but as yet there have been only a few reports on its outcome compared with bone marrow transplantation (BMT), especially for adults. We studied the clinical outcomes of 113 adult patients with hematologic malignancies who received unrelated BM transplants (n = 45) or unrelated CB transplants (n = 68). We analyzed the hematopoietic recovery, rates of graft-versus-host disease (GVHD), risks of transplantation-related mortality (TRM) and relapse, and disease-free survival (DFS) using Cox proportional hazards models. The time from donor search to transplantation was significantly shorter among CB transplant recipients (median, 2 months) than BM transplant recipients (median, 11 months; P < .01). Multivariate analysis demonstrated slow neutrophil (P < .01) and platelet (P < .01) recoveries in CBT patients compared with BMT patients. Despite rapid tapering of immunosuppressants after transplantation and infrequent use of steroids to treat severe acute GVHD, there were no GVHD-related deaths among CB transplant recipients compared with 10 deaths of 24 among BM transplant recipients. Unrelated CBT showed better TRM and DFS results compared with BMT (P = .02 and P < .01, respectively), despite the higher human leukocyte antigen mismatching rate and lower number of infused cells. These data strongly suggest that CBT could be safely and effectively used for adult patients with hematologic malignancies.

scholarly journals Survival of Group A Erythrocytes Following Bone Marrow Transplantation for Reconstitution of Lymphopenic Hypogammaglobulinemia

Blood ◽  
1971 ◽  
Vol 38 (1) ◽  
pp. 60-65 ◽  
Author(s):  
M. M. AZAR ◽  
R. A. GATTI ◽  
E. J. YUNIS ◽  
J. SWANSON ◽  
R. A. GOOD
Keyword(s):  
Bone Marrow ◽  
Immune System ◽  
Bone Marrow Transplantation ◽  
Blood Group ◽  
Marrow Transplantation ◽  
Bone Marrow Transplants ◽  
Blood Group A ◽  
Group A ◽  
Immunological Destruction

Abstract The survival of chromium-labeled group A erythrocytes was measured in a patient who had previously received two bone marrow transplants for reconstitution of lymphopenic hypogammaglobulinemia. The patient was of blood group A before transplantation; the donor of blood group O. The patient’s erythrocytes are now virtually 100% group O. Anti-B titers are present; anti-A antibodies are not demonstrable. The cells producing these isohemagglutinins are of donor origin; the donor has anti-A titers of 1:64 in saline and 1:256 by antihuman globulin test as well as anti-B titers. No evidence of immunological destruction of group A erythrocytes was found in this patient suggesting that the immune system of the donor may have become tolerant of the group A substance of the recipient.

Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital

2002 ◽  
Vol 49 (suppl_1) ◽  
pp. 51-55 ◽  
Author(s):  
Olle Ringdén
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Amphotericin B ◽  
Marrow Transplantation ◽  
Fungal Infections ◽  
University Hospital ◽  
Fungal Colonization ◽  
Double Blind Study ◽  
Transplant Recipients ◽  
Double Blind

Abstract Our substantial experience in several trials with AmBisome in adult and paediatric patients undergoing transplantation has shown this formulation of amphotericin B to be safe and effective in therapeutic and prophylactic use. AmBisome has shown a significant reduction in fungal colonization and invasive Candida infections compared with placebo in a prospec-tive, double-blind study in bone marrow transplantation, and eradication of invasive fungal infections in 86% of 14 children undergoing bone marrow transplantation. The main side effects of AmBisome use are elevations in serum potassium and creatinine, but these lead to very few withdrawals from treatment. Compared with conventional amphotericin B, AmBisome is very expensive, but its much improved safety profile and proven efficacy make it an excellent agent for management of invasive fungal disease in transplant recipients.

scholarly journals Bone marrow transplantation for Fanconi anemia

Blood ◽  
1995 ◽  
Vol 86 (7) ◽  
pp. 2856-2862 ◽  
Author(s):  
E Gluckman ◽  
AD Auerbach ◽  
MM Horowitz ◽  
KA Sobocinski ◽  
RC Ash ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Fanconi Anemia ◽  
Marrow Transplantation ◽  
Bone Marrow Failure ◽  
Unrelated Donor ◽  
Bone Marrow Transplants ◽  
Transplant Outcome ◽  
Factors Associated ◽  
Increased Risk

Fanconi anemia is a genetic disorder associated with diverse congenital abnormalities, progressive bone marrow failure, and increased risk of leukemia and other cancers. Affected persons often die before 30 years of age. Bone marrow transplantation is an effective treatment, but there are few data regarding factors associated with transplant outcome. We analyzed outcomes of HLA-identical sibling (N = 151) or alternative related or unrelated donor (N = 48) bone marrow transplants for Fanconi anemia performed between 1978 and 1994 and reported to the International Bone Marrow Transplant Registry. Fanconi anemia was documented by cytogenetic studies in all cases. Patient, disease, and treatment factors associated with survival were determined using Cox proportional hazards regression. Two-year probabilities (95% confidence interval) of survival were 66% (58% to 73%) after HLA-identical siblings transplants and 29% (18% to 43%) after alternative donor transplants. Younger patient age (P .0001), higher pretransplant platelet counts (P = .04), use of antithymocyte globulin (P = .005), and use of low-dose (15 to 25 mg/kg) cyclophosphamide plus limited field irradiation (P = .009) for pretransplant conditioning and cyclosporine for graft-versus-host disease prophylaxis (P = .002) were associated with increased survival. Bone marrow transplants are effective therapy for Fanconi anemia. The adverse impact of increasing age and lower pretransplant platelet count on transplant outcome favors earlier intervention, especially when there is an HLA-identical sibling donor.

Bone Marrow Transplants

PEDIATRICS ◽  
1990 ◽  
Vol 85 (2) ◽  
pp. 235-236
Author(s):  
ANGELA KENT OGDEN ◽  
C. PHILIP STEUBER
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Government Agencies ◽  
Bone Marrow Transplants ◽  
The Public ◽  
New Therapies ◽  
Dying Children

To the Editor.— Bone marrow transplantation has been increasingly undertaken and found effective for a variety of otherwise incurable diseases. As with all new therapies, the economic and ethical impact of the procedure requires continuing reevaluation. Durbin1 clearly stated the dilemmas faced by transplantation centers, insurance carriers, government agencies, and the public in general. Furman2 offered a limited view of transplantation and stated that bone marrow transplantation "may be neither ethical nor imperative as a therapy for dying children."

Sign in / Sign up

Export Citation Format

Share Document